Maribavir

This classification denotes a purine antagonist and antiviral agent with the molecular formula C15H19Cl2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PTB4X93HE1, chemically known as 5,6-dichloro-n-(1-methylethyl)-1-beta-l-ribofuranosyl-1h-benzimidazol-2-amine but generally known as maribavir, which bears US NIH Compound Identifier 122872. European Medicines Agency schedules Maribavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03090MIG. The term MARIBAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules maribavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule maribavir under HS 29349990 and SITC 51579. As of Q4 2014, MARIBAVIR remains the US FDA Preferred Term for this commodity. Maribavir bears US NLM identifiers UMLS ID C1508759 and NCI Concept Code C82254. SMILES: Clc1cc2n(C3OC(C(O)C3O)CO)c(NC(C)C)nc2cc1Cl.